Trump Won’t Force Medicaid to Cover GLP-1S for Obesity. A Few States Are Doing It Anyway.

Ex-FDA chief feeds speculation Trump is on the ‘fat shot’ - Washington Examiner

His team says President Donald Trump has lost 20-30 pounds the old-fashioned way, but speculation is growing that he might have had a little help. Former Food and Drug Administration Commissioner David Kessler suggested this week that the president might be using what Trump has dubbed the “fat shot,” a GLP-1 variation. “They’ve not denied it, let’s put it this way. They’ve not said he is on it, right? But they’ve not denied it,” said Kessler whi…

GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice

An early driver of Type 2 diabetes mellitus (T2D) is ectopic fat accumulation, especially in the liver, that impairs insulin sensitivity. In T2D, GLP-1R/GCGR dual-agonists reduce glycaemia, body weight and hepatic steatosis. Here, we utilize cotadutide, a well characterized GLP-1R/GCGR dual-agonist, and demonstrate improvement of insulin sensitivity during hyperinsulinemic euglycemic clamp following sub-chronic dosing in male, diet-induced obese…

Trump won’t force Medicaid to cover GLP-1S for obesity. A few states are doing it anyway.

When Page Campbell's doctor recommended she try an injectable prescription drug called Wegovy to lose weight before scheduling bariatric surgery, she readily agreed.

Trump Won’t Force Medicaid to Cover GLP-1s for Obesity. A Few States Are Doing It Anyway.

CHARLESTON, S.C. — When Page Campbell’s doctor recommended she try an injectable prescription drug called Wegovy to lose weight before scheduling bariatric surgery, she readily agreed. “I’ve struggled with my weight for so long,” said Campbell, 40, a single mother of two. “I’m not opposed to trying anything.” In early April, about four weeks after she’d started taking Wegovy, Campbell said she hadn’t experienced any side effects, such as nausea …

Trump won't force Medicaid to cover GLP-1s for obesity. A few states are doing it anyway.

Late last year, South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But access remains limited.

Hot topic: Could obesity medicines gobble up other drugs’ profits? – Optimum Strategic CommunicationsLink to: Poolbeg Pharma plc – Proposed Retail Offer to raise up to £100,000Scroll to top

Great news from the European Congress on Obesity (ECO) in Malaga earlier this week: obesity drugs such as Wegovy and Mounjaro slash the chances of dying from a range of killer diseases including strokes, heart attacks and various cancers. Roughly speaking, they halve the risk.  GLP-1s appear to “affect the biology of diseases of ageing”, […]